Biocon Shares In Focus After USFDA Approves Pebrilzo, Its Fifth Oncology Biosimilar, For HER2-Positive Breast Cancer

Biocon has secured USFDA approval for Pebrilzo, its fifth oncology biosimilar, for HER2-positive breast cancer. The drug's US launch is expected in the third quarter of 2028.
Shares of Biocon came into prominence in early trading on Monday, 16 November, after the company secured US Food and Drug Administration (USFDA) approval for Pebrilzo, its biosimilar version of the cancer drug Perjeta. The approval marks the company's fifth USFDA-approved oncology biosimilar.
The company said the approval would expand its range of treatment options for patients with HER2-positive breast cancer. Pebrilzo is a biosimilar of pertuzumab, a monoclonal antibody used to treat this form of cancer.
Despite the latest regulatory approval, Biocon shares were trading lower in Monday's session as the day progressed. The stock was down 0.70% at ₹361.50 as of 11:11 am on the National Stock Exchange of India (NSE). Biocon stocks have lost over 6% so far in 2026 and around 14% over the past 12 months.
What Is Pebrilzo And Which Patients Can Use It?
Pebrilzo works by blocking HER2 receptors on cancer cells. HER2-positive breast cancer is an aggressive form of the disease. According to the company's regulatory filing, the USFDA has approved the drug for patients with both metastatic and early-stage HER2-positive breast cancer.
Biocon said Pebrilzo is designed to have no clinically meaningful differences from Perjeta in terms of safety, quality and effectiveness.
However, the drug's label carries warnings about potential heart problems and risks to unborn babies. It also requires patients to undergo regular cardiac checks. Women receiving the treatment must follow contraception requirements during therapy, according to the filing.
Regulatory And Launch Timeline For Pebrilzo
The US approval follows a regulatory development in Europe. In September, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended marketing approval for Pebrilzo.
The European recommendation covers HER2-positive breast cancer across multiple stages of the disease. Biocon is also preparing for the US commercial launch.
Under a licensing agreement with Genentech, Pebrilzo is expected to enter the US market in the third quarter of 2028. The approval adds another product to the company's oncology biosimilar portfolio, although the commercial launch remains more than a year away.
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer

Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.
At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.
When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.
Right Tools, Rich Insights










